Novo Nordisk A/S Files For Regulatory Approval Of Liraglutide 3 Mg For The Treatment Of Obesity

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bagsvaerd, Denmark, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Bagsværd, Denmark, 20 December 2013 - Novo Nordisk today announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or who are overweight with comorbidities. The company filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA).

Help employers find you! Check out all the jobs and post your resume.

Back to news